Thinle Chodon to Proto-Oncogene Proteins B-raf
This is a "connection" page, showing publications Thinle Chodon has written about Proto-Oncogene Proteins B-raf.
Connection Strength
0.910
-
The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations. Clin Cancer Res. 2010 Dec 15; 16(24):6040-8.
Score: 0.334
-
Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Clin Cancer Res. 2014 Jul 01; 20(13):3446-57.
Score: 0.106
-
A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov. 2014 Jan; 4(1):69-79.
Score: 0.102
-
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2014 Jan; 4(1):80-93.
Score: 0.102
-
BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res. 2012 Aug 15; 72(16):3928-37.
Score: 0.092
-
Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun. 2012 Mar 06; 3:724.
Score: 0.091
-
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010 Dec 16; 468(7326):973-7.
Score: 0.083